Skip to main content

Table 2 Unadjusted and adjusted odds ratios and 95% confidence intervals (CI) for sustained virological response after treatment with peginterferon and ribavirin in 432 chronically HCV infected patients, according to predictor variables

From: Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study

  Predictor variable Odds ratio (95% CI)
unadjusted
Odds ratio (95% CI)
adjusted
Gender Female 1 1
  Male 0.92 (0.61-1.39) 0.80 (0.50-1.27)
Nationality European 1 1
  Non-European 2.53 (1.23-5.21) 3.03 (1.20-7.67)
Route of infection Non-IDU 1 1
  IDU 1.59 (0.91-2.77) 1.43 (0.76-2.69)
  Unknown 1.38 (0.77-2.49) 1.21 (0.61-2.41)
Age Age ≤ 45 years at treatment initiation 1 1
  Age > 45 years at treatment initiation 0.38 (0.25-0.58) 0.47 (0.30-0.74)
Genotype 1 1 1
  2 or 3 3.01 (1.97-4.60) 2.31 (1.45-3.69)
HCV-RNA ≤ 600.000 IU/mL 1 1
  > 600.000 IU/mL 0.53 (0.36-0.79) 0.70 (0.45-1.10)
ALT Less than 2 × UNL* 1 1
  More than 2 × UNL 1.39 (0.94-2.06) 1.40 (0.91-2.16)
Treating department (speciality) Gastroenterology/Hepatology 1 1
  Infectious Diseases 1.03 (0.69-1.55)) 0.93 (0.59-1.49)
Liver biopsy Not cirrhosis 1  
  Cirrhosis 0.44 (0.25-0.79) §  
Treatment completion As shceduled 1 1
  With dose reduction 0.55 (0.34-0.90) 0.57 (0.33-0.96)
  Ended before scheduled 0.22 (0.12-0.38) 0.26 (0.14-0.47)
  1. UNL, upper normal limit
  2. *2 × UNL = ALT > 70 IU/L (female), ALT > 100 IU/L (male)
  3. §Only 250 of the 432 patients had a liver biopsy done. Thisparameter is therefore not included in the adjusted analyses.
  4. IDU, Intravenous drug use